Saturday, July 5, 2008

Clinico-genomics publications

Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, Hainfellner JA, Heppner FL, Dietrich PY, Zimmer Y, Cairncross JG, Janzer RC, Domany E, Delorenzi M, Stupp R, Hegi ME. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008 Jun 20;26(18):3015-24

Sunday, June 1, 2008

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.

Publication related online materials

Model 1:In the general GBM population

Model 2:In patients treated by RT/TMZ (MGMT methylation status unavailable)

Model 3: In patients with partial or total resection and treated by RT/TMZ (MGMT methylation status available)

More on clinical prognostic factors for Glioblastoma

Other publications


Spectroscopy

Recommended reading :

Spectroscopie atomique - Émile Biémont

P Quinet, T Gorlia and E Biémont. Allowed and forbidden transitions in highly ionized neon-like atoms (Ni XIX-U LXXXIII). 1991 Phys. Scr. 44 164-183 - pdf - citations to this article

Cost Effectiveness analyses

Recommended reading :

Statistical Analysis of Cost-Effectiveness Data (Statistics in Practice) (Hardcover) by Andrew R. Willan (Author), Andrew H. Briggs (Author) "There is a growing expectation from health care policymakers that evidence supporting the cost-effectiveness of new health care interventions, particularly pharmaceuticals, be provided along with..." (more)

Tjan-Heijnen VC, Caleo S, Postmus PE, Ardizzoni A, Burghouts JT, Buccholz E, Biesma B, Gorlia T, Crott R, Giaccone G, Debruyne C, Manegold C; European Organisation for Research Treatment of Cancer-Lung Cancer Group and Health Economics Unit ; Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923); Ann Oncol. 2003 Feb;14(2):248-57.

Neymark N, Gorlia T, Adriaenssen I, Baron B, Piccart M ; Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium. Pharmacoeconomics. 2002;20(7):485-97.

Neymark N, Adriaenssen I, Gorlia T, Caleo S, Bolla M.; Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ. 2002 Apr;11(3):233-48.

Clinico-Genomics ressources database

Consult my Clinico-Genomics ressource database.
http://www.gorlia.net/genomics/Genomics_list.asp
Please suggest new entry by answering this post.

Treatment of other cancers

Head and Neck

Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1695-704.

Breast

Beex L, Rose C, Mouridsen H, Jassem J, Nooij M, Estape J, Paridaens R, Piccart M, Gorlia T, Lardenoije S, Baila L. Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863). Eur J Cancer. 2006 Dec;42(18):3178-85. Epub 2006 Oct 12.

Colorectal - Chronotherapy

Coudert B, Focan C, Genet D, Giacchetti S, Cvickovic F, Zambelli A, Fillet G, Chollet P, Amoroso D, Van Der Auwera J, Lentz MA, Marreaud S, Baron B, Gorlia T, Biville F, Lévi F.A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971. Chronobiol Int. 2008 Sep;25(5):680-96.

Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Canon JL, Adenis A, Lo Re G, Carvalho C, Schueller J, Anciaux N, Lentz MA, Baron B, Gorlia T, Lévi F; European Organisation for Research and Treatment of Cancer Chronotherapy Group. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol. 2006 Aug 1;24(22):3562-9.

Gastric

Conroy T, Etienne PL, Adenis A, Ducreux M, Paillot B, Oliveira J, Seitz JF, Francois E, Van Cutsem E, Wagener DJ, Kohser F, Daamen S, Praet M, Gorlia T, Baron B, Wils J; European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Ann Oncol. 2002 May;13(5):721-9.

Prognostic, Diagnostic, Treatment of Brain Tumors

Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, Hainfellner JA, Heppner FL, Dietrich PY, Zimmer Y, Cairncross JG, Janzer RC, Domany E, Delorenzi M, Stupp R, Hegi ME. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008 Jun 20;26(18):3015-24 Preusser M, Janzer RC, Felsberg J, Reifenberger G, Hamou MF, Diserens AC, Stupp R, Gorlia T, Marosi C, Heinzl H, Hainfellner JA, Hegi M. Anti-O6-Methylguanine-Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker. Brain Pathol. 2008 Apr 8 [Epub ahead of print]Click here to read.

Idbaih A, Kouwenhoven M, Jeuken J, Carpentier C, Gorlia T, Kros JM, French P, Teepen JL, Delattre O, Delattre JY, van den Bent M, Hoang-Xuan K.,Chromosome 1p loss evaluation in anaplastic oligodendrogliomas.Neuropathology. 2008 Feb 26.

Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008 Jan;9(1):29-38. Epub 2007 Dec 21. Comment in: Lancet Oncol. 2008 Jan;9(1):5-6 -more

Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella-Branger D, Giangaspero F, Giannini C, Mokhtari K, Mørk SJ, Paetau A, Reifenberger G, van den Bent MJ. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol. 2007 Jun;66(6):545-51.

Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006 Jun 1;24(16):2563-9.

Preusser M, Heinzl H, Gelpi E, Schonegger K, Haberler C, Birner P, Marosi C, Hegi M, Gorlia T, Hainfellner JA. Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors: a translational research project of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Cancer. 2006 Jul 1;107(1):162-70.

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005 Mar 10;352(10):997-1003.

Treatment of Brain Tumors

Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, Frenay M, Rampling R, Stupp R, Kros JM, Heinrich MC, Gorlia T, Lacombe D, van den Bent MJ; European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.J Clin Oncol. 2008 Oct 1;26(28):4659-65.

Hildebrand J, Gorlia T, Kros JM, Afra D, Frenay M, Omuro A, Stupp R, Lacombe D, Allgeier A, van den Bent MJ; on behalf of the EORTC Brain Tumour Group investigators.Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). Eur J Cancer. 2008 Jan 11

van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006 Jun 20;24(18):2715-22.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96.

van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros JM, van der Rijt CC, Vecht ChJ, Allgeier A, Gorlia T; European Organization for Research and Treatment of Cancer Brain Tumor Group. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol. 2003 Jul 1;21(13):2525-8.

My publications

My publications via NCBI (Pubmed.gov) s

Consult also the EORTC Brain Tumor Group bibliography - EORTC Head and Neck bibliography

Career



Current Appointment (1999-...):
Thierry Gorlia is a member of the team allocated by the EORTC Data Center to provide scientific and logistic support to EORTC Brain Tumor and Translational Research Unit in the conduct of their cancer clinical trials. As a biostatistician of the EORTC, he provides statistical advice and expertise in the design, implementation, conduct, analysis and publications of the group’s clinical trials. He recently participated to the conduct and analysis of the EORTC 24971 of Taxotere in inoperable squamous cell carcinoma of the Head & Neck.
He reports to the Assistant Director for Biostatistics and work in close cooperation with the other members of his teams (coordinating physician, data manager,…), and with other units of the Data Center for particular projects.

His duties and responsibilities are:

• to advise the clinical group and the study coordinator on the optimal statistical design to be used in the conduct of their studies
• to help the study coordinator to write the study outline
• to coordinate the development of some of the protocols of his groups via the protocol help desk ,
• to handle the submission of all amendments for those protocols for which he coordinated the development.
• to be responsible for all statistical analyses of the data, whether for data monitoring committees, group meetings, congresses or for the publication of the results
• to present the results of these statistical analyses to the IDMC or to the groups
• to review all abstracts and publications written by investigators on the basis of Data Center reports and to write the statistical sections (material and methods, sometimes results) of the publications
• to maintain an up-to-date knowledge of the statistical techniques necessary for the proper design of trials and the analysis of the data (by reading publications in biostatistical journals, attending statistical meetings, etc)
• to identify and/or develop the software needed to carry out his work (meta-analysis, competing risks, …)
• to contribute to scientific research projects undertaken by the Data Center or the groups

• to carry out research on methodology related to the design, conduct or analysis of cancer clinical trials and to submit papers for publication
• to submit abstracts for presentation at statistical or medical meetings
• to give lectures during educational sessions or courses organized either by the EORTC or by other organizations.

Previous position at the EORTC Headquarter:
Biostatistican of the Health Economic Unit (June 1999-November 2003). Biostatistican of the Quality of Life Unit (June 1999-October 2001).

Previous Appointments:

Consulting Statistician for SPSS Belgium in Leuven (September 1998 – May 1999)
Consulting Actuary for Unison Consultant Europe and Towers Perrin (April 1995-September 1998)
Research Actuary for The Free University of Brussels (ULB) (November 1992-November 1994)
Student actuary for AXA Insurance and Le Man Assurance (1990-1992)
Consulting Statistician for SONECOM (November 1995-November 2000)